Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
References (103)
- et al.
Bevacizumab-current status and future directions
Ann Oncol
(2005) - et al.
Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
J Urol
(1999) - et al.
Role ofvascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
Am J Pathol
(1998) - et al.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
Lancet
(2000) - et al.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
Sernin Oncol
(2003) - et al.
High vascularity in the peripheral region of non-small cell lung can cer tissue is associated with tumor progression
Lung Cancer
(2001) - et al.
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials
Lancet Oncol.
(2005) - et al.
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
Cancer Res
(2005) - et al.
Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies
Ann Pharmacother
(2004) - et al.
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
J Clin Oncol
(2005)
Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers
Cancer Control
(2002)
Angiogenesis and lung cancer: Prognostic and therapeutic implications
J Clin Oncol
(2005)
Bevacizumab in combination chemotherapy forcolorectal and othercancers
Am J Health Syst Pharm
(2005)
Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
Cancer Res
(1998)
Blood flow influences vascular growth during tumour angiogenesis
Br J Cancer
(1999)
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
N Engl J Med
(1995)
Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions
J Clin Oncol
(2005)
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
J Clin Oncol
(2005)
VEGF-targeted therapy: Therapeutic potential and recent advances
Oncologist
(2005)
Translating angiogenesis research into the clinic: The challenges ahead
Br J Radiol
(2003)
(2004)
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Angiogenesis
(2004)
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results ofa randomized phase II trial
J Clin Oncol
(2005)
Normalizing tumorvasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Nat Med
(2001)
Approval package for: Application number STN-125085/0. Review and evaluation of pharmacology data
(August 15, 2006)
Expanding the clinical development of bevacizumab
Oncologist
(2004)
Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
Anticancer Res
(1999)
Evidence of efficacy: Researchers investigating markers for angiogenesis inhi bitors
J Natl Cancer Inst
(2003)
Impact of vascular endothelial growth factor-A expression, thrombospondin 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
J Clin Oncol
(2006)
Angiogenic factors as tumor markers
Invest New Drugs
(1997)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
J Clin Oncol
(2005)
The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC)
Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
J Clin Oncol.
(2001)
Preclinical pharmacokinetics, interspecies scaling, and tissue distribu tion of a humanized monoclonal antibody against vascular endothelial growth factor
J Pharmacol Exp Ther.
(1999)
Application number STN-125085/0. Clinical pharmacology/toxicology review
(August 15, 2006)
Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients
Director, Office of Drug Evaluation VI, Office of New Drugs, CIDER
(February 26, 2004)
Measuring response in solid tumors: Comparison of RECIST and WHO re sponse criteria
Jpn J Clin Oncol.
(2003)
New guidelines to evaluate the response to treatment in solid tumors
J Natl Cancer Inst.
(2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
J Clin Oncol.
(2000)
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
Cancer Chemother Pharmacol.
(2004)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
N Engl J Med.
(2000)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment
J Clin Oncol.
(2004)
Systemic therapy for colorectal cancer
N Engl J Med.
(2005)
Critical evaluation of current treatments in metastatic colorectal cancer
Oncologist
(2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
J Clin Oncol.
(2004)
Targeted therapy of colorectal cancer: Clinical experience with bevacizumab
Oncologist
(2004)
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer
Clin Oncol.
(1998)
Systemic therapy for metastatic colorectal cancer: Current options, current evidence
J Clin Oncol.
(2005)
Cited by (431)
Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada
2024, Clinical Colorectal CancerInhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma
2023, Computers in Biology and MedicineNanobiotechnology-based treatment strategies for malignant relapsed glioma
2023, Journal of Controlled Release
Copyright © 2006 Published by Elsevier Inc.